Antimicrobial resistance, including growing malaria parasite resistance to treatments, remains a major challenge of our time. There is a serious concern that resistance to artemisinin-based treatments will proliferate in Africa, the continent with over 90 percent of malaria cases and deaths. The implications for malaria morbidity and mortality could be disastrous if this resistance persists. We must act fast and decisively on anti-malarial resistance by combining innovation with intersectional approaches that look like how issues such as gender and poverty limit access to proper diagnosis and treatment while fueling resistance. Join RBM and partners on an insightful conversation to ensure that malaria is not left behind in the conversations and decisions on antimicrobial resistance. Anti-malarial resistance is a threat to our future, and we must act now.
